Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Drug Discovery Today
|
September 17, 2014
Ketamine: repurposing and redefining a multifaceted drug
David E Potter, Mahua Choudhury
Experimental Eye Research
|
November 12, 2003
Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits
Juanita Dortch-Carnes, David E Potter
CNS Drug Reviews
|
July 12, 2005
Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties
Juanita Dortch-Carnes, David E Potter
The Journal of Pharmacology and Experimental Therapeutics
|
April 19, 2002
Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C
Juanita Dortch-Carnes, David E Potter
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
September 12, 2002
Ocular hypotension induced by electroacupuncture
Teh-Ching Chu, David E Potter
Pharmacology
|
September 11, 2002
Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies
Juanita Dortch-Carnes, David E Potter
Current Eye Research
|
March 27, 2003
Pharmacological evidence of a role for prejunctional imidazoline (I(1)) receptors in ocular function
Miller J Ogidigben, David E Potter
Current Pharmaceutical Design
|
July 4, 2012
Non-analgesic effects of opioids: neuroprotection in the retina
Shahid Husain, Yasir Abdul, David E Potter
Experimental Eye Research
|
October 18, 2002
Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-Opioid receptors
Karen R M Russell, David E Potter
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
January 23, 2003
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent
Teh-Ching Chu, Qing He, David E Potter
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Drug Discovery Today
|
September 17, 2014
Ketamine: repurposing and redefining a multifaceted drug
David E Potter, Mahua Choudhury
Experimental Eye Research
|
November 12, 2003
Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits
Juanita Dortch-Carnes, David E Potter
CNS Drug Reviews
|
July 12, 2005
Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties
Juanita Dortch-Carnes, David E Potter
The Journal of Pharmacology and Experimental Therapeutics
|
April 19, 2002
Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C
Juanita Dortch-Carnes, David E Potter
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
September 12, 2002
Ocular hypotension induced by electroacupuncture
Teh-Ching Chu, David E Potter
Pharmacology
|
September 11, 2002
Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies
Juanita Dortch-Carnes, David E Potter
Current Eye Research
|
March 27, 2003
Pharmacological evidence of a role for prejunctional imidazoline (I(1)) receptors in ocular function
Miller J Ogidigben, David E Potter
Current Pharmaceutical Design
|
July 4, 2012
Non-analgesic effects of opioids: neuroprotection in the retina
Shahid Husain, Yasir Abdul, David E Potter
Experimental Eye Research
|
October 18, 2002
Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-Opioid receptors
Karen R M Russell, David E Potter
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
January 23, 2003
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent
Teh-Ching Chu, Qing He, David E Potter
Page
of 2